Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

British Journal of Haematology - Tập 120 Số 1 - Trang 44-52 - 2003
John D. Shaughnessy1, Erming Tian1, Jeffrey R. Sawyer1, Jason McCoy2, Guido Tricot1, Joth Jacobson2, Elias Anaissie1, Maurizio Zangari1, Athanasios Fassas1, Firas Muwalla1, Christopher Morris1, Bart Barlogie1
1Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, and
2the Southwest Oncology Group, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Tóm tắt

Summary. Cytogenetic abnormalities of chromosome 13 (CA 13) and those detected by fluorescence in situ hybridization (FISH 13) have both been associated with poor prognosis in multiple myeloma (MM) patients. The prognostic implications of CA, FISH 13 and other standard laboratory parameters were examined in the first 231 patients enrolled in Total Therapy II, an intensive cytotoxic chemotherapy programme with tandem autotransplants. Three‐year projections of event‐free survival (EFS) and overall survival (OS) were 71% and 77% respectively. CA 13 was detected in 14% and significantly correlated with FISH 13 (present in 51%), tumour burden, proliferative activity and lactic dehydrogenase (LDH). Both EFS and OS were significantly shorter in patients with CA 13, FISH 13, LDH ≥ 190 U/l, β2 microglobulin ≥ 4 mg/l and C reactive protein ≥ 4·0 mg/l; other CA was an additional risk factor for OS. Two‐thirds of CA 13 patients were identified by FISH 13 and plasma‐cell‐labelling index (PCLI) ≥ 0·4%; however, PCLI failed to identify additional risk groups in FISH subsets. Although present in considerably fewer patients, CA 13 imparted more rapid relapse (61% at 3 years) and death (43% at 3 years) than FISH 13 (38% and 35%; P = 0·02 and 0·1 respectively) and should be part of the initial work‐up of patients with MM.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199607113350204

10.1182/blood.V97.9.2574

10.1172/JCI112033

10.1182/blood.V93.1.55.401k04_55_65

Barlogie B., 2000, Long term follow up of 169 patients receiving a Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM), Blood, 96, 2213a

Barlogie B., 2001, Total Therapy II (TTII) for newly diagnosed multiple myeloma (MM); preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial Total Therapy I (TTI) (n = 231), Blood, 98, 2857a

Cox D.R., 1972, Regression models and life‐tables, Journal of the Royal Statistical Society, Series B, 34, 187

Dao D.D., 1994, Deletion of the retinoblastoma gene in multiple myeloma, Leukemia, 8, 1280

Debes Marun C., 2001, In multiple myeloma the combination of an elevated plasma cell labeling index (PCLI) and chromosome 13 deletion, detected by interphase FISH, can identify patients with chromosome 13 abnormalities detected by karyotype, Blood, 98, 658a

Desikan R., 1999, DCEP consolidation chemotherapy (CC) after 2 cycles of melphalan‐based high dose therapy (HDT): high incidence of CR and superior outcome in comparison with matched historical controls, Blood, 94, 1411a

Desikan R., 2000, Results of high dose therapy for 1,000 patients with multiple myeloma. Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, Blood, 95, 4008, 10.1182/blood.V95.12.4008

10.1182/blood.V66.2.380.380

Drach J., 1995, Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization, Cancer Research, 55, 3854

10.1182/blood.V97.6.1566

Flactif M., 1995, Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma, Leukemia, 9, 2109

Gould J., 1988, Plasma cell karyotype in multiple myeloma, Blood, 71, 453, 10.1182/blood.V71.2.453.453

Greipp P., 1993, Plasma cell labeling index and beta‐2‐microglobulin predict survival independent of thymidine kinase and C‐reactive protein in multiple myeloma, Blood, 81, 3382, 10.1182/blood.V81.12.3382.3382

Kaplan E.L., 1958, Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 5, 457, 10.1080/01621459.1958.10501452

Mantel N., 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemotherapy Reports, 50, 163

Perez‐Simon J.A., 1998, Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes, Blood, 91, 3366, 10.1182/blood.V91.9.3366

10.1016/S0950-3536(05)80257-4

10.1016/0165-4608(94)00284-I

10.1046/j.1365-2141.1998.00657.x

Shaughnessy J., 2000, High incidence of chromosome 13 deletion in multiple myeloma detected by multi‐probe interphase FISH, Blood, 96, 1505, 10.1182/blood.V96.4.1505

10.1056/NEJM199911183412102

10.1182/blood.V86.11.4250.bloodjournal86114250

10.1182/blood.V87.3.1196.bloodjournal8731196

10.1016/0021-9681(67)90082-3

10.1046/j.1365-2141.1996.d01-2939.x

Zhan F., 2001, Global gene expression profiles can be used to accurately predict chromosome 13 deletion in multiple myeloma, Blood, 98, 1553a

10.1182/blood.V99.5.1745

Zojer N., 2000, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization, Blood, 95, 1925, 10.1182/blood.V95.6.1925

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 120 Số 1

44-52

Thông tin tác giả